Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Translocator Protein 18 kDa PET Radioligands with High Affinities Regardless of Genotype

Posted Jul 24 2013 8:00pm

Description of Invention:
This technology relates to a group of Translocator protein 18 kDa (TSPO) radioligands for Positron Emission Tomography (PET) that are specific and accurate, regardless of genotype. TSPO is a mitochondrial protein expressed in inflammatory cells, which is a marker for neuroinflammation. Neuroinflammation is symptomatic of many neuropsychiatric and neurodegenerative disorders, such as multiple sclerosis, stroke, epilepsy, dementia, and traumatic brain injuries. Monitoring and quantifying TSPO 18 kDa with radioligands in PET may have clinical application in understanding, diagnosing and treating many neuropsychiatric disorders. However, current TSPO 18 kDa radioligands either lack specificity or, due to TSPO polymorphisms, have highly variable inter-subject sensitivities depending on genotype. These new ligands are specific and accurate, regardless of genotype, allowing simplified interpretation and quantification of the binding signal.

Applications:
Biomarker or diagnostic for neuroinflammation

Advantages:
Specific and accurate, regardless of genotype

Development Status:
  • Early-stage
  • Pre-clinical
  • In vivo data available (animal)


Inventors:
Victor W Pike (NIMH)
Robert B Innis (NIMH)
Federico P Da Settimo (University of Pisa)
Giorgio Stefancich (University of Trieste)
Sabrina Taliani (University of Pisa)
Sabrina Castellano (University of Pisa)
Claudia Martini (University of Pisa)


Patent Status:
HHS, Reference No. E-262-2012/0
US, Application No. 61/777,542 filed 12 Mar 2013


Relevant Publication:
  1. Oh U, et al. [ PMID 20872081 ]
  2. Kreisl WC, et al. [ PMID 19822787 ]
  3. Hirvonen J, et al. [ PMID 22238156 ]
  4. Kreisl WC, et al. [ PMID 23775979 ]


Collaborative Research Opportunity:
The National Institute of Mental Health is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize TSPO radioligands for monitoring inflammation. For collaboration opportunities, please contact Suzanne Winfield at winfiels@mail.nih.gov .


For Licensing Information Please Contact:
Edward (Tedd) Fenn
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: fennea@mail.nih.gov
Phone: 301-435-5031
Fax: 301-402-0220


Ref No: 2596

Updated: 07/2013

Post a comment
Write a comment:

Related Searches